Fig. 3.
Chronic A61603 treatment improved myofilament force development. A: myofilament force development in demembranated right ventricular (RV) muscle samples at various levels of activator Ca2+ concentration ([Ca2+]), expressed as pCa (−log [Ca2+]). Compared with the nonfailing RV, force development was impaired in the bleomycin (Bleo) model. Force development was higher with concurrent A61603 treatment. B: maximum Ca2+-activated force (Fmax) determined by fitting data to the Hill equation (35). The reduction of Fmax in the bleomycin model (****P < 0.0001) was attenuated by A61603 (***P < 0.001).